Qiagen’s (QGEN) “Buy” Rating Reaffirmed at Goldman Sachs

Qiagen (NYSE:QGEN)‘s stock had its “buy” rating reissued by Goldman Sachs in a research note issued to investors on Wednesday, Stock Target Advisor reports.

Several other research firms have also commented on QGEN. JPMorgan Chase reaffirmed a “neutral” rating on shares of Qiagen in a research report on Thursday, May 3rd. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research report on Thursday, May 3rd. ValuEngine raised shares of Qiagen from a “hold” rating to a “buy” rating in a report on Thursday, May 3rd. Deutsche Bank reissued a “buy” rating and issued a $40.00 target price (up from $38.00) on shares of Qiagen in a report on Tuesday, April 24th. Finally, DZ Bank reissued a “neutral” rating on shares of Qiagen in a report on Thursday, April 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $38.50.

Qiagen opened at $35.09 on Wednesday, according to Marketbeat Ratings. Qiagen has a 52 week low of $34.89 and a 52 week high of $35.09. The stock has a market cap of $7.98 billion, a PE ratio of 27.66, a price-to-earnings-growth ratio of 2.19 and a beta of 1.03. The company has a quick ratio of 1.94, a current ratio of 2.14 and a debt-to-equity ratio of 0.52.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Stock Target Advisor

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply